Hyperuricemia - Pipeline Review, H2 2016

Date: September 30, 2016
Pages: 71
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HC5E53D488EEN
Leaflet:

Download PDF Leaflet

Hyperuricemia - Pipeline Review, H2 2016
Hyperuricemia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia - Pipeline Review, H2 2016, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.

High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 4, 4 and 4 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Hyperuricemia.

Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Hyperuricemia Overview
Therapeutics Development
Pipeline Products for Hyperuricemia - Overview
Pipeline Products for Hyperuricemia - Comparative Analysis
Hyperuricemia - Therapeutics under Development by Companies
Hyperuricemia - Therapeutics under Investigation by Universities/Institutes
Hyperuricemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Hyperuricemia - Products under Development by Companies
Hyperuricemia - Products under Investigation by Universities/Institutes
Hyperuricemia - Companies Involved in Therapeutics Development
Allena Pharmaceuticals, Inc.
AstraZeneca Plc
CymaBay Therapeutics, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Nippon Chemiphar Co., Ltd.
Nobelpharma Co., Ltd.
Polaris Pharmaceuticals, Inc.
Teijin Pharma Limited
Hyperuricemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(allopurinol + lesinurad) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALLN-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arhalofenate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
febuxostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JPH-367 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NC-2500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NC-2700 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegadricase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pyruvic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-4640 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMX-049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verinurad - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XEN-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperuricemia - Dormant Projects
Hyperuricemia - Discontinued Products
Hyperuricemia - Product Development Milestones
Featured News & Press Releases
Jun 15, 2016: Scottish Medicines Consortium Accepts Adenuric (Febuxostat) for the Prevention and Treatment of Hyperuricaemia and Predicts Savings for NHS Scotland
May 23, 2016: Teijin Pharma’s Feburic (Febuxostat) Approved as Indication for Cancer Chemotherapy-Induced Hyperuricemia
Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11
Jun 30, 2015: New Indication for Teijin Pharma’s Febuxostat in Europe
Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat
Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric
Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat
Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat
Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea
May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan
Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67
Jan 21, 2011: Teijin Pharma Receives Approval Of TMX-67 For Treating Hyperuricemia In Japan
Oct 27, 2010: Teijin Pharma Launches TMX-67 In Canada
Mar 09, 2010: Menarini Launches ADENURIC (Febuxostat) In Europe
Mar 05, 2010: Launch by Menarini and Ipsen of Adenuric (febuxostat) in France for the treatment of chronic hyperuricemia in gout
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 71

LIST OF TABLES

Number of Products under Development for Hyperuricemia, H2 2016
Number of Products under Development for Hyperuricemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Hyperuricemia - Pipeline by Allena Pharmaceuticals, Inc., H2 2016
Hyperuricemia - Pipeline by AstraZeneca Plc, H2 2016
Hyperuricemia - Pipeline by CymaBay Therapeutics, Inc., H2 2016
Hyperuricemia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
Hyperuricemia - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016
Hyperuricemia - Pipeline by Nobelpharma Co., Ltd., H2 2016
Hyperuricemia - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016
Hyperuricemia - Pipeline by Teijin Pharma Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Hyperuricemia - Dormant Projects, H2 2016
Hyperuricemia - Discontinued Products, H2 2016 59

LIST OF FIGURES

Number of Products under Development for Hyperuricemia, H2 2016
Number of Products under Development for Hyperuricemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Hyperuricemia - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 68 pages
Kaketsuken K.K. - Product Pipeline Review - 2015 US$ 1,200.00 Sep, 2015 · 24 pages
Mycosis Fungoides - Pipeline Review, H2 2014 US$ 1,500.00 Oct, 2014 · 65 pages

Ask Your Question

Hyperuricemia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: